NCT02467790View on ClinicalTrials.gov

Polyethylene Glycol Loxenatide Pharmacokinetics Study in Subjects With Normal and Insufficiency Renal Function

PHASE1UnknownINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

March 31, 2016

Study Completion Date

May 31, 2016

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

PEX168

PEX 168: 200µg,Subcutaneous,one time.

Trial Locations (1)

Unknown

RECRUITING

Third Xiangya Hospital, Central South Univety, Changsha

Sponsors
All Listed Sponsors
lead

Jiangsu Hansoh Pharmaceutical Co., Ltd.

INDUSTRY

NCT02467790 - Polyethylene Glycol Loxenatide Pharmacokinetics Study in Subjects With Normal and Insufficiency Renal Function | Biotech Hunter | Biotech Hunter